When Grammy-nominated singer-songwriter Aloe Blacc contracted COVID-19 despite being fully vaccinated and boosted, he set out to fund new research that could deliver better long-term solutions for infectious disease outbreaks. What he discovered almost right away was that driving progress in biotech is not as simple as writing a large check. Regulatory bodies require detailed, formal commercialization roadmaps to approve project advancement, traditional standalone philanthropy cannot carry early-stage science through costly clinical trial phases, and navigating academic intellectual property licensing comes with huge barriers that casual donations cannot overcome.

Today, Blacc is bootstrapping his own drug development platform focused on pancreatic cancer — an aggressive, understudied disease that kills 90% of all patients diagnosed. He has taken a deliberate, data-first approach to growth: Blacc is intentionally waiting to solicit funding from his wide professional network until peer-reviewed published research can definitively prove out his platform’s potential.

Don’t miss the latest conversation where Aloe Blacc joins host Rebecca Bellan on TechCrunch’s Equity podcast. The episode digs into what happens when a creator chooses to build a company from scratch instead of just writing checks as an outside investor. Blacc also opens up about how he is watching artificial intelligence reshape both the biotech and music industries in real time, and shares his unfiltered thoughts on which stakeholders actually come out ahead in this new wave of innovation.

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify, and all major podcast platforms today. You can also follow the Equity show on X and Threads at the official handle @EquityPod for the latest episode updates and behind-the-scenes content.